Celladon Corp Share Price Nasdaq
Equities
US15117E1073
Biotechnology & Medical Research
Sales 2024 * | 2.52Cr 209.97Cr | Sales 2025 * | 3.27Cr 271.88Cr | Capitalization | 37.79L 31Cr |
---|---|---|---|---|---|
Net income 2024 * | -2.4Cr -199.83Cr | Net income 2025 * | -90L -75Cr | EV / Sales 2024 * | 0.15 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.12 x |
P/E ratio 2024 * |
-0.16
x | P/E ratio 2025 * |
-0.71
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
Latest transcript on Celladon Corp
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 14/17/14 |
James Vollins
CMP | Compliance Officer | 55 | 13/23/13 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 18/22/18 | |
Thomas Dietz
CHM | Chairman | 60 | 22/16/22 |
David Apelian
CEO | Chief Executive Officer | 59 | 14/17/14 |
1st Jan change | Capi. | |
---|---|---|
-0.09% | 4.21TCr | |
+49.62% | 4.2TCr | |
-4.96% | 2.92TCr | |
+11.18% | 2.6TCr | |
-21.95% | 1.89TCr | |
+8.61% | 1.32TCr | |
+24.73% | 1.22TCr | |
+28.31% | 1.22TCr | |
-6.26% | 1.14TCr |